In conclusion, we suggest that serum leptin can identify NAFLD without obesity as a confounding factor, whereas adiponectin combined with specific serum lipids might be advantageous for NAFL vs. NASH stratification. The gene discussed is ADIPOQ; the disease is metabolic dysfunction-associated steatohepatitis.